News

Home>News
News2020-07-17T11:41:26-04:00
Jul 222021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

July 22nd, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , , , , |

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau.  Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU).  At YSU, Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department and his team will immediately proceed to the next step ...

Jul 62021

Halberd Corporation CEO Letter

July 6th, 2021|Categories: Featured, Update Letter|

Q2-21 Accomplishments and Q3 Plans Jackson Center, PA, July 6, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) As we began the second quarter, the company, along with the rest of the country, was focused on developing antibodies against Covid-19 that could be used as therapeutic and/or diagnostic tools.  Because of the apparent effectiveness of the vaccines and other measures, Covid cases have decreased dramatically, necessitating a reprioritization of Halberd’s research ...

Jun 302021

Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process

June 30th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , |

Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies.  This simplified method for the removal of disease-causing antigen(s) utilizes more conventional medical equipment found in hospitals and clinics and utilizes our patented extracorporeal treatment process.  The method promises to simplify the ...

Jun 212021

Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

June 21st, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , |

Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means.  Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to the combined population of the states of Florida and New York. The seven (7) stages in Halberd’s program are as ...

Jun 162021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

June 16th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , , , , , , |

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process.  These three antigens, which are found in Cerebral Spinal Fluid (CSF), are associated with the formation of neurofibrillary tangles concomitant with Alzheimer’s Disease.  Conjugation of these antibodies with gold-coated ...

Jun 92021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

June 9th, 2021|Categories: Featured, Investor News, News|Tags: , , , , , , , |

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease.  By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the disease. Dr. Mitchell S. Felder, Halberd Corporation’s Chief Technical Officer and the inventor of Halberd’s technology, stated, “We believe the ...

Go to Top